Reata Pharmaceuticals Inc. - Our Science - Our Technologies - Nrf2 Activators
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes | NEJM
Bardoxolone Methyl | ≥99%(HPLC) | Selleck | IκB/IKK inhibitor
Bardoxolone conjugation enables targeted protein degradation of BRD4 | Scientific Reports
Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells | Molecular Pharmacology
Therapeutic Effects of Nrf2 Activation by Bardoxolone Methyl in Chronic Heart Failure | Journal of Pharmacology and Experimental Therapeutics
Bardoxolone methyl (RTA 402) | Nrf2 Activator | MedChemExpress
Antioxidants | Free Full-Text | Pharmacotherapy against Oxidative Stress in Chronic Kidney Disease: Promising Small Molecule Natural Products Targeting Nrf2-HO-1 Signaling | HTML
BARDOXOLONE METHYL
Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney | American Society of Nephrology
Pharmacodynamics of bardoxolone methyl. A, levels of NF- k B, cyclin... | Download Scientific Diagram
Schematic image of potential mechanism by which bardoxolone methyl... | Download Scientific Diagram
Targeting crosstalk between Nrf-2, NF-κB and androgen receptor signaling in prostate cancer
Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease - ScienceDirect
Bardoxolone Methyl | ≥99%(HPLC) | Selleck | IκB/IKK inhibitor
Bardoxolone - an overview | ScienceDirect Topics
Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its | DDDT
NF-kB Signaling Pathway products from Selleck Chemicals
Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Imp
Can Activation of NRF2 Be a Strategy against COVID-19?: Trends in Pharmacological Sciences
Cancers | Free Full-Text | Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer | HTML
Increased albuminuria in bardoxolone methyl–treated type 2 diabetes patients: mere reflection of eGFR improvement? - Kidney International
Bardoxolone methyl | 218600-53-4
Molecules | Free Full-Text | Transcription Factors as Therapeutic Targets in Chronic Kidney Disease | HTML
Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease | Signal Transduction and Targeted Therapy
Bardoxolone methyl (RTA 402) | ≥99%(HPLC) | IκB/IKK inhibitor | AdooQ®
